NCT03600259

Brief Summary

Acute myocardial infarction(AMI) is the most serious manifestation of coronary artery disease. AMI is characterized by high mortality, high disability, and high cost. However, multicenter research on AMI with large sample size in Tianjin or even China is limited. By including AMI in 36 hospitals,this multicenter study will capture the changes in epidemiological trends ,analyze the status of treatment in Tianjin, and explore the best treatment strategies.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
13,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2018

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2018

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

July 6, 2018

Completed
20 days until next milestone

First Posted

Study publicly available on registry

July 26, 2018

Completed
4.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2023

Completed
11 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2023

Completed
Last Updated

November 2, 2022

Status Verified

November 1, 2022

Enrollment Period

5 years

First QC Date

July 6, 2018

Last Update Submit

November 1, 2022

Conditions

Myocardial Infarction, Acute

Keywords

Myocardial InfarctionCoronary DiseaseCoronary Artery DiseaseMyocardial Ischemia

Outcome Measures

Primary Outcomes (1)

  • Cardiac death

    Due to recent cardiac causes (eg myocardial infarction, low-volume heart failure, fatal arrhythmias), any deaths from unknown and unexplained deaths and all surgical-related deaths (including treatment-related deaths) will be attributed to cardiac death.Unless there is a clear non-cardiological cause, all deaths are considered heart disease. Specifically, even patients with concurrent potentially fatal non-cardiac diseases (such as cancer, infections) who have any accidental death should be classified as having a heart attack.

    1 year

Secondary Outcomes (5)

  • Major adverse cardiovascular events

    10 days on average (during hospitalization)

  • Major adverse cardiovascular events

    1 month

  • Major adverse cardiovascular events

    3 months

  • Major adverse cardiovascular events

    6 months

  • Major adverse cardiovascular events

    1 year

Study Arms (1)

Acute Myocardial Infarction

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Hospitalized patients with acute myocardial infarction from 36 hospitals in Tianjin were enrolled between January 2015 and January 2020

You may qualify if:

  • Hospitalized patients with acute myocardial infarction according to Cardiac biomarker values \[Selective cardiac troponin (cTc) elevation and/or decline detection, at least one value exceeds the 99% reference limit (URL) and at least one of the following:（1）Symptoms of myocardial ischemia；（2）New or suspected new obvious ST-T changes or new left bundle branch block (LBBB)；（3）ECG pathological Q waves；（4）Image evidence of recent loss of viable myocardium, or new regional wall motion abnormalities；（5）Coronary thrombosis confirmed by angiography or autopsy.\]

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Tianjin Chest Hospital

Tianjin, Tianjin Municipality, 300051, China

RECRUITING

Related Publications (1)

  • Gao MD, Zhang EY, Liu YY, Li XW, Xiao JY, Sun GY, Liu Y. Intracoronary pressure gradient measurement in acute myocardial infarction patients with the no-reflow phenomenon during primary percutaneous coronary intervention. Chin Med J (Engl). 2020 Apr 5;133(7):766-772. doi: 10.1097/CM9.0000000000000709.

    PMID: 32149760DERIVED

MeSH Terms

Conditions

Myocardial InfarctionCoronary DiseaseCoronary Artery DiseaseMyocardial Ischemia

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular DiseasesVascular DiseasesInfarctionIschemiaPathologic ProcessesPathological Conditions, Signs and SymptomsNecrosisArteriosclerosisArterial Occlusive Diseases

Study Officials

  • Yin Liu, M.D

    Tianjin Chest Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Yin Liu, M.D

CONTACT

+86-13502152283tami2018@163.com

Jixiang Wang, PHD

CONTACT

+86-13752068790tami2018@163.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
OTHER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Director, Cardiology Department, Tianjin Chest Hospital

Study Record Dates

First Submitted

July 6, 2018

First Posted

July 26, 2018

Study Start

January 1, 2018

Primary Completion

January 1, 2023

Study Completion

December 1, 2023

Last Updated

November 2, 2022

Record last verified: 2022-11

Locations

CN(1)